Potential Role of Akkermansia muciniphila in Parkinson’s Disease and Other Neurological/Autoimmune Diseases

Abstract

The composition of the gut microbiota, including Akkermansia muciniphila (A. muciniphila), is altered in many neurological diseases and may be involved in the pathophysiological processes of Parkinson’s disease (PD). A. muciniphila, a mucin-degrading bacterium, is a potential next-generation microbe that has anti-inflammatory properties and is responsible for keeping the body healthy. As the role of A. muciniphila in PD has become increasingly apparent, we discuss the potential link between A. muciniphila and various neurological diseases (including PD) in the current review.

Keywords

Akkermansia muciniphila / gut microbiota / neurological diseases / Parkinson’s disease

References

[1] TravagliRA, BrowningKN, CamilleriM. Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol, 2020, 17(11): 673-685

[2] FangP, KazmiSA, JamesonKG, et al.. The Microbiome as a Modifier of Neurodegenerative Disease Risk. Cell Host Microbe, 2020, 28(2): 201-222

[3] FangX. Potential role of gut microbiota and tissue barriers in Parkinson’s disease and amyotrophic lateral sclerosis. Int J Neurosci, 2016, 126(9): 771-776

[4] SundmanMH, ChenNK, SubbianV, et al.. The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease. Brain Behav Immun, 2017, 66: 31-44

[5] Perez-PardoP, DodiyaHB, BroersenLM, et al.. Gut-brain and brain-gut axis in Parkinson’s disease models: Effects of a uridine and fish oil diet. Nutr Neurosci, 2018, 21(6): 391-402

[6] SampsonTR, DebeliusJW, ThronT, et al.. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell, 2016, 167(6): 1469-1480.e12

[7] DerrienM, VaughanEE, PluggeCM, et al.. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J Syst Evol Microbiol, 2004, 54: 1469-1476 Pt 5

[8] O’ToolePW, MarchesiJR, HillC. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microbiol, 2017, 2: 17057

[9] ZhaiR, XueX, ZhangL, et al.. Strain-Specific Anti-inflammatory Properties of Two Akkermansia muciniphila Strains on Chronic Colitis in Mice. Front Cell Infect Microbiol, 2019, 9: 239

[10] LiJ, LinS, VanhouttePM, et al.. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice. Circulation, 2016, 133(24): 2434-2446

[11] DepommierC, EverardA, DruartC, et al.. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med, 2019, 25(7): 1096-1103

[12] ShinNR, LeeJC, LeeHY, et al.. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 2014, 63(5): 727-735

[13] BarcenaC, Valdes-MasR, MayoralP, et al.. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat Med, 2019, 25(8): 1234-1242

[14] HeinzelS, AhoVTE, SuenkelU, et al.. Gut Microbiome Signatures of Risk and Prodromal Markers of Parkinson Disease. Ann Neurol, 2020, 88(2): 320-331

[15] KeshavarzianA, GreenSJ, EngenPA, et al.. Colonic bacterial composition in Parkinson’s disease. Mov Disord, 2015, 30(10): 1351-1360

[16] Hill-BurnsEM, DebeliusJW, MortonJT, et al.. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov Disord, 2017, 32(5): 739-749

[17] Heintz-BuschartA, PandeyU, WickeT, et al.. The nasal and gut microbiome in Parkinson’s disease and idiopathic rapid eye movement sleep behavior disorder. Mov Disord, 2018, 33(1): 88-98

[18] NishiwakiH, ItoM, IshidaT, et al.. Meta-Analysis of Gut Dysbiosis in Parkinson’s Disease. Mov Disord, 2020, 35(9): 1626-1635

[19] CirsteaMS, YuAC, GolzE, et al.. Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson’s Disease. Mov Disord, 2020, 35(7): 1208-1217

[20] BedarfJR, HildebrandF, CoelhoLP, et al.. Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson’s disease patients. Genome Med, 2017, 9(1): 39

[21] UngerMM, SpiegelJ, DillmannKU, et al.. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat Disord, 2016, 32: 66-72

[22] HertelJ, HarmsAC, HeinkenA, et al.. Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson’s Disease. Cell Rep, 2019, 29(7): 1767-1777.e8

[23] VandeputteD, KathagenG, D’HoeK, et al.. Quantitative microbiome profiling links gut community variation to microbial load. Nature, 2017, 551(7681): 507-511

[24] Tettamanti BoshierFA, SrinivasanS, LopezA, et al.. Complementing 16S rRNA Gene Amplicon Sequencing with Total Bacterial Load To Infer Absolute Species Concentrations in the Vaginal Microbiome. mSystems, 2020, 5(2): e00777-19

[25] MillerPG, BonnMB, FranklinCL, et al.. TNFR2 Deficiency Acts in Concert with Gut Microbiota To Precipitate Spontaneous Sex-Biased Central Nervous System Demyelinating Autoimmune Disease. J Immunol, 2015, 195(10): 4668-4684

[26] CekanaviciuteE, YooBB, RuniaTF, et al.. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci USA, 2017, 114(40): 10 713-10 718

[27] CekanaviciuteE, ProbstelAK, ThomannA, et al.. Multiple Sclerosis-Associated Changes in the Composition and Immune Functions of Spore-Forming Bacteria. mSystems, 2018, 3(6): e00083-18

[28] LiuS, RezendeRM, MoreiraTG, et al.. Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila. Cell Host Microbe, 2019, 26(6): 779-794.e8

[29] HoggE, AthreyaK, BasileC, et al.. High Prevalence of Undiagnosed Insulin Resistance in Non-Diabetic Subjects with Parkinson’s Disease. J Parkinsons Dis, 2018, 8(2): 259-265

[30] NamGE, KimSM, HanK, et al.. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med, 2018, 15(8): e1002640

[31] De Pablo-FernandezE, GoldacreR, PakpoorJ, et al.. Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology, 2018, 91(2): e139-e142

[32] CharvinD, MedoriR, HauserRA, et al.. Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov, 2018, 17(11): 804-822

[33] BoscoD, PlastinoM, CristianoD, et al.. Dementia is associated with insulin resistance in patients with Parkinson’s disease. J Neurol Sci, 2012, 315(1–2): 39-43

[34] KahnSE, HullRL, UtzschneiderKM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444(7121): 840-846

[35] SchnurrTM, JakupovicH, CarrasquillaGD, et al.. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. Diabetologia, 2020, 63(7): 1324-1332

[36] SannaS, van ZuydamNR, MahajanA, et al.. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet, 2019, 51(4): 600-605

[37] LarsenN, VogensenFK, van den BergFW, et al.. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One, 2010, 5(2): e9085

[38] Aron-WisnewskyJ, PriftiE, BeldaE, et al.. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut, 2019, 68(1): 70-82

[39] CaniPD, de VosWM. Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Front Microbiol, 2017, 8: 1765

[40] DaoMC, BeldaE, PriftiE, et al.. Akkermansia muciniphila abundance is lower in severe obesity, but its increased level after bariatric surgery is not associated with metabolic health improvement. Am J Physiol Endocrinol Metab, 2019, 317(3): E446-E459

[41] GiannoudakiE, Hernandez-SantanaYE, MulfaulK, et al.. Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction. Nat Commun, 2019, 10(1): 4003

[42] DaoMC, EverardA, Aron-WisnewskyJ, et al.. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut, 2016, 65(3): 426-436

[43] SchneebergerM, EverardA, Gomez-ValadesAG, et al.. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci Rep, 2015, 5: 16643

[44] EverardA, BelzerC, GeurtsL, et al.. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA, 2013, 110(22): 9066-9071

[45] DepommierC, Van HulM, EverardA, et al.. Pasteurized Akkermansia muciniphila increases whole-body energy expenditure and fecal energy excretion in diet-induced obese mice. Gut Microbes, 2020, 11(5): 1231-1245

[46] Zhang L, Qin Q, Liu M, et al. Akkermansia muciniphila can reduce the damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in streptozotocin-induced diabetic rats. Pathog Dis, 2018,76(4)

[47] PlovierH, EverardA, DruartC, et al.. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med, 2017, 23(1): 107-113

[48] WuF, GuoX, ZhangM, et al.. An Akkermansia muciniphila subtype alleviates high-fat diet-induced metabolic disorders and inhibits the neurodegenerative process in mice. Anaerobe, 2020, 61: 102138

[49] GreerRL, DongX, MoraesAC, et al.. Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism. Nat Commun, 2016, 7: 13329

[50] SuH, MoJ, NiJ, et al.. Andrographolide Exerts Antihyperglycemic Effect through Strengthening Intestinal Barrier Function and Increasing Microbial Composition of Akkermansia muciniphila. Oxid Med Cell Longev, 2020, 2020: 6538930

[51] FujisakaS, UsuiI, NawazA, et al.. Bofutsushosan improves gut barrier function with a bloom of Akkermansia muciniphila and improves glucose metabolism in mice with diet-induced obesity. Sci Rep, 2020, 10(1): 5544

[52] LiN, WangX, SunC, et al.. Change of intestinal microbiota in cerebral ischemic stroke patients. BMC Microbiol, 2019, 19(1): 191

[53] StanleyD, MooreRJ, WongCHY. An insight into intestinal mucosal microbiota disruption after stroke. Sci Rep, 2018, 8(1): 568

[54] BlacherE, BashiardesS, ShapiroH, et al.. Potential roles of gut microbiome and metabolites in modulating ALS in mice. Nature, 2019, 572(7770): 474-480

[55] TalbotK, WangHY, KaziH, et al.. Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest, 2012, 122(4): 1316-1338

[56] de la MonteSM. Insulin resistance and Alzheimer’s disease. BMB Rep, 2009, 42(8): 475-481

[57] Baglietto-VargasD, ShiJ, YaegerDM, et al.. Diabetes and Alzheimer’s disease crosstalk. Neurosci Biobehav Rev, 2016, 64: 272-287

[58] NagpalR, NethBJ, WangS, et al.. Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer’s disease markers in subjects with mild cognitive impairment. EBioMedicine, 2019, 47: 529-542

[59] OuZ, DengL, LuZ, et al.. Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer’s disease. Nutr Diabetes, 2020, 10(1): 12

[60] YangY, ZhongZ, WangB, et al.. Early-life high-fat diet-induced obesity programs hippocampal development and cognitive functions via regulation of gut commensal Akkermansia muciniphila. Neuropsychopharmacology, 2019, 44(12): 2054-2064

[61] KuhnP, KalariyaHM, PoulevA, et al.. Grape polyphenols reduce gut-localized reactive oxygen species associated with the development of metabolic syndrome in mice. PLoS One, 2018, 13(10): e0198716

[62] RoopchandDE, CarmodyRN, KuhnP, et al.. Dietary Polyphenols Promote Growth of the Gut Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced Metabolic Syndrome. Diabetes, 2015, 64(8): 2847-2858

[63] de la Cuesta-ZuluagaJ, MuellerNT, Corrales-AgudeloV, et al.. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care, 2017, 40(1): 54-62

[64] Etxeberria U, Hijona E, Aguirre L, et al. Pterostilbene-induced changes in gut microbiota composition in relation to obesity. Mol Nutr Food Res, 2017,61(1)

[65] HansenCH, KrychL, NielsenDS, et al.. Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia, 2012, 55(8): 2285-2294

[66] Guevara-CruzM, Flores-LopezAG, Aguilar-LopezM, et al.. Improvement of Lipoprotein Profile and Metabolic Endotoxemia by a Lifestyle Intervention That Modifies the Gut Microbiota in Subjects With Metabolic Syndrome. J Am Heart Assoc, 2019, 8(17): e012401

[67] MaD, WangAC, ParikhI, et al.. Ketogenic diet enhances neurovascular function with altered gut microbiome in young healthy mice. Sci Rep, 2018, 8(1): 6670

[68] SelaU, EulerCW, Correa da RosaJ, et al.. Strains of bacterial species induce a greatly varied acute adaptive immune response: The contribution of the accessory genome. PLoS Pathog, 2018, 14(1): e1006726

[69] LeventhalGE, BoixC, KuechlerU, et al.. Strain-level diversity drives alternative community types in millimetre-scale granular biofilms. Nat Microbiol, 2018, 3(11): 1295-1303

[70] GuoX, LiS, ZhangJ, et al.. Genome sequencing of 39 Akkermansia muciniphila isolates reveals its population structure, genomic and functional diverisity, and global distribution in mammalian gut microbiotas. BMC Genomics, 2017, 18(1): 800

[71] YanY, NguyenLH, FranzosaEA, et al.. Strain-level epidemiology of microbial communities and the human microbiome. Genome Med, 2020, 12(1): 71

[72] GuoX, ZhangJ, WuF, et al.. Different subtype strains of Akkermansia muciniphila abundantly colonize in southern China. J Appl Microbiol, 2016, 120(2): 452-459

[73] AnsaldoE, SlaydenLC, ChingKL, et al.. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis. Science, 2019, 364(6446): 1179-1184

[74] Fujio-VejarS, VasquezY, MoralesP, et al.. The Gut Microbiota of Healthy Chilean Subjects Reveals a High Abundance of the Phylum Verrucomicrobia. Front Microbiol, 2017, 8: 1221

[75] XiaoY, AnguloMT, FriedmanJ, et al.. Mapping the ecological networks of microbial communities. Nat Commun, 2017, 8(1): 2042

[76] BashanA, GibsonTE, FriedmanJ, et al.. Universality of human microbial dynamics. Nature, 2016, 534(7606): 259-262

[77] BartolomaeusTUP, BirknerT, BartolomaeusH, et al.. Quantifying Technical Confounders in Microbiome Studies. Cardiovasc Res, 2021, 117(3): 863-875

[78] TangQ, JinG, WangG, et al.. Current Sampling Methods for Gut Microbiota: A Call for More Precise Devices. Front Cell Infect Microbiol, 2020, 10: 151

[79] PanekM, Cipcic PaljetakH, BaresicA, et al.. Methodology challenges in studying human gut microbiota — effects of collection, storage, DNA extraction and next generation sequencing technologies. Sci Rep, 2018, 8(1): 5143

[80] LoucaS, PolzMF, MazelF, et al.. Function and functional redundancy in microbial systems. Nat Ecol Evol, 2018, 2(6): 936-943

[81] XiaoY, AnguloMT, LaoS, et al.. An ecological framework to understand the efficacy of fecal microbiota transplantation. Nat Commun, 2020, 11(1): 3329